Close menu




June 8th, 2021 | 10:15 CEST

The Power of Digital Media - AMC, ProSieben, Tencent, Aspermont

  • Investments
Photo credits: pixabay.com

Sell in May and go away...in 2021, it has not yet worked. The weather in June is much warmer and the markets are rushing from one all-time high to the next. The DAX reached a new high yesterday at 15,732. The mood was outstanding, especially when it came to vehicle values. However, the excesses were slightly slowed down at AMC Entertainment. Now that the Company has placed three capital increases, some calm has returned. We look at a few special situations in this advanced bull market.

time to read: 4 minutes | Author: André Will-Laudien
ISIN: US00165C1045 , DE000PSM7770 , KYG875721634 , AU000000ASP3

Table of contents:


    AMC Entertainment - What madness!

    AMC was again at the center of another wave of buying by retail investors last week, discussing the stock on forums like Reddit's "WallStreetBets" and breathing new life into the "meme stock" phenomenon. GameStop exemplified how to quickly gain 1,600% in January by running hot on forums. The share price has halved again after the high but is still trading at a dizzying height.

    It looks like things are going to be a little different for AMC. The Company's stock was up "only" a little over 83% last week. The movie theater operator is already up 2,160% this year, giving some major institutions paper losses of nearly USD 4 billion, according to the latest available data from S3 Partners. The high volatility in the stock is making life difficult even for options traders.

    A Reuters analysis of options data and interviews with market participants, including a Wall Street banker and a fund manager with USD 30 billion in assets, show that some institutional investors have entered into complex options trades. They are all aiming for AMC stock to turn down someday, too. Typically, irrational moves of this magnitude do not last for a long time, and some professional traders are betting against it.

    Meanwhile, AMC Company management warns that its stock is "grossly overvalued" and has already issued more than USD 1 billion in new shares. Providers such as Melvin Capital lost half of their invested assets in GameStop shorts in January, and overall hedge fund losses total about USD 11 billion, according to data from research and analysis firm Ortex. It will be interesting to see where this madness will lead.

    ProSiebenSat.1 - A long way to go, little imagination

    ProSiebenSat.1 Media SE is one of the leading European media groups. Its core business consists of advertising-financed free TV, which is received in around 50 million households in Germany, Austria and Switzerland. With 15 free and pay-TV stations, the Company is well-positioned to reach all commercially relevant target groups in German-speaking countries.

    ProSieben can be found on all digital platforms and is in permanent competition with RTL Luxembourg and Axel Springer Medien. With the U21 final at the weekend, they landed a hit in prime time with up to 39% market share. The share price took a bit of a hit last week after the broadcaster expressed skepticism about possible mergers at its annual general meeting. The shares lost 5.5%; after deducting the dividend discount, the loss was still 3%. The Italian media giant Mediaset is very interested in ProSieben and, as a significant shareholder, advocates closer cooperation between the two media companies.

    From a chart perspective, the EUR 16.50 mark should provide solid support, while the EUR 19 mark must first be overcome on the upside before the share price can continue to rise. At present, there is no urgent need for action.

    Tencent - Another IPO in the USA

    There is also strategic news from Tencent. The Chinese media and software giant presents its next exit. Kanzhun Ltd, the owner of Chinese online recruitment platform Boss Zhipin, is looking to raise up to USD 912 million in its US IPO, venturing into the market at a time when many other companies prefer to wait on the sidelines.

    If the Company can place shares at the high end of the price range, it would be the second-largest IPO by a Chinese company in the US since software firm Tuya Inc.'s USD 947 million IPO in March. Several Chinese companies have recently put their plans to go public in the US on hold as investor sentiment toward growth companies, especially from Asia, has soured and IPOs have been unsuccessful. Insurtech firm Waterdrop Inc. has fallen 30% below its IPO price since its debut in early May. Waterdrop launched on the stock market despite warnings from the Chinese government, and an official investigation into its business model from Beijing has already been threatened.

    The Tencent share can currently defend the range of EUR 60 to 66 only, with difficulty. A chart-technical buy signal is waiting at the EUR 72 mark. At EUR 55, it should end on the downside.

    Aspermont Ltd. - Strong growth in the user base

    Aspermont Ltd. from Australia is a specialist in digital content and marketing. The media group represents a well-connected capital market companion for many companies in the commodities sector. Aspermont earns through ever-increasing advertising revenue, which comes from its growing user base. This is scaling in its purest form because as the reach increases, the Company's development and IT costs are spread over more and more paying users. Currently, the average revenue per user (ARPU) is about USD 1,000 per year.

    In recent years, Aspermont has undergone a comprehensive restructuring at all company levels - corporate, operational and technological. More than 250,000 monthly active users now browse the website, generating a total of 7.5 million digital touchpoints. Currently, they have about 4 million active users in the global mining sector, with 22% of customers from Australia but only a manageable 7% from Asia. The size of the Asian market, which has not yet been addressed, shows enormous potential for the coming years.

    Aspermont intends to introduce new types of subscription and service platforms in the coming years. Given the size of the global audience already in place, real-time analysis of behavioral data alone could enable another expansion step into the world of Big Data. Regardless of whether this data is used in-house or sold on the market, a future-oriented profit model arises from both levels. It is also intended to set up a digital financing platform.

    The Aspermont share is still far too cheap, with a capitalization of around AUD 67 million. The stock can be traded liquid in Germany and is an absolute bargain compared to some NASDAQ data giants like Palantir or Qualtrics.


    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may in the future hold shares or other financial instruments of the mentioned companies or will bet on rising or falling on rising or falling prices and therefore a conflict of interest may arise in the future. conflict of interest may arise in the future. The Relevant Persons reserve the shares or other financial instruments of the company at any time (hereinafter referred to as the company at any time (hereinafter referred to as a "Transaction"). "Transaction"). Transactions may under certain circumstances influence the respective price of the shares or other financial instruments of the of the Company.

    Furthermore, Apaton Finance GmbH reserves the right to enter into future relationships with the company or with third parties in relation to reports on the company. with regard to reports on the company, which are published within the scope of the Apaton Finance GmbH as well as in the social media, on partner sites or in e-mails, on partner sites or in e-mails. The above references to existing conflicts of interest apply apply to all types and forms of publication used by Apaton Finance GmbH uses for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and etc. on news.financial. These contents serve information for readers and does not constitute a call to action or recommendations, neither explicitly nor implicitly. implicitly, they are to be understood as an assurance of possible price be understood. The contents do not replace individual professional investment advice and do not constitute an offer to sell the share(s) offer to sell the share(s) or other financial instrument(s) in question, nor is it an nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but rather financial analysis, but rather journalistic or advertising texts. Readers or users who make investment decisions or carry out transactions on the basis decisions or transactions on the basis of the information provided here act completely at their own risk. There is no contractual relationship between between Apaton Finance GmbH and its readers or the users of its offers. users of its offers, as our information only refers to the company and not to the company, but not to the investment decision of the reader or user. or user.

    The acquisition of financial instruments entails high risks that can lead to the total loss of the capital invested. The information published by Apaton Finance GmbH and its authors are based on careful research on careful research, nevertheless no liability for financial losses financial losses or a content guarantee for topicality, correctness, adequacy and completeness of the contents offered here. contents offered here. Please also note our Terms of use.


    Der Autor

    André Will-Laudien

    André Will-Laudien

    Born in Munich, he first studied economics and graduated in business administration at the Ludwig-Maximilians-University in 1995. As he was involved with the stock market at a very early stage, he now has more than 30 years of experience in the capital markets.

    About the author



    Related comments:

    Commented by Armin Schulz on October 27th, 2026 | 05:21 CET

    Pharma Stocks with a Future: Bayer, BioNxt Solutions and Novo Nordisk Expand Their Pipelines

    • Bayer
    • BioNxt Solutions
    • Novo Nordisk
    • Investments
    • Active ingredients
    • Dosage forms
    • Thin film
    • Orally disintegrating film
    • Cladribine
    • Diabetes
    • Obesity
    • Weight-loss pill

    No pharmaceutical company can rely on its bestsellers forever. Eventually, patent protection expires, generic manufacturers enter the market, and margins come under pressure. Companies that fail to replenish their product pipelines risk being left behind. That is why substantial sums are currently flowing into new active ingredients, manufacturing facilities and innovative drug delivery methods. Bayer plans to invest USD 2.2 billion in a pharmaceutical plant in Ohio. Smaller developers such as BioNxt Solutions are exploring new formulations and delivery methods for established active ingredients. At the end of September, Novo Nordisk agreed to license an oral drug candidate, including an upfront payment of USD 300 million. We take a closer look at Bayer, BioNxt Solutions and Novo Nordisk.

    Read

    Commented by Carsten Mainitz on October 14th, 2026 | 05:30 CEST

    Tungsten, Weapons and Growth: Almonty, Rheinmetall and Deutz Under Review. Is This an Opportunity in a Megatrend?

    • Tungsten
    • Raw materials
    • Critical raw materials
    • Geopolitics
    • Defence industry
    • Armaments
    • Military
    • Supply chains
    • Investments

    The stock market is not linear. Greed and fear, excessive optimism or excessive scepticism—all of these drive markets. Only the future will tell what is cheap or expensive today. The stocks mentioned above are at precisely this point. Secure supply chains, access to raw materials and defence readiness are high on the agenda of Western governments. These long-term trends play strongly into the hands of defence companies and raw material producers. Almonty, in particular, as a producer of the critical raw material tungsten, holds a leading position in the sector. Where do the greatest opportunities lie for investors now?

    Read

    Commented by Carsten Mainitz on October 14th, 2026 | 05:25 CEST

    Who Profits When Patents Expire? The Billion-Euro Race Between Formycon, Fresenius and Pfizer

    • Biosimilar
    • FDA
    • Milestone
    • Cancer therapy
    • Pharma
    • Patents
    • Investments

    When patent protection for high-revenue biopharmaceuticals expires, a billion-euro market for follow-on products emerges. Michael Sen, head of the German healthcare group Fresenius SE, cites an impressive figure. By 2035, this could generate around EUR 180 billion in revenue. In particular, biosimilars, biotechnologically produced follow-on medicines that are highly similar in composition to the original medicine and equivalent in quality, efficacy and safety, are forecast to grow significantly. Moreover, biosimilars can strengthen competition and reduce treatment costs. Formycon stands out as a pure play. The company recently reached a crucial milestone. The US Food and Drug Administration (FDA) accepted the marketing authorisation application, the first publicly known application of its kind, for FYB206, a biosimilar candidate to the cancer medicine Keytruda, for review. Keytruda generates around USD 32 billion in annual revenue, making it the world's highest-revenue medicine. Fresenius is strengthening its positioning in the biosimilar sector through an acquisition. Pfizer needs new growth drivers. Who is best positioned for the year-end rally?

    Read